This trial sought to evaluate the potential advantages of combined mifepristone–misoprostol versus misoprostol-only for earlymedical abortion. The study was double-blind randomized placebo controlled and enrolled 441 pregnant women (<63 days LMP). The mifepristone–misoprostol group (n=220) received 200 mg of mifepristone on day 1 and 800 μg buccal misoprostol followed by placebo 3 hours later on day 2. The misoprostol-only group (n=221) received placebo on day 1 and 1600 μg of misoprostol (2 doses of 800 μg, given 3 hours apart) on day 2. The results demonstrated that the combined regimen was significantly more effective than the misoprostol-only protocol for early medical abortion.
Access the abstract.View All Resources